Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to learn more about symptoms and gastrointestinal lesions associated with taking myfortic® by switching patients to a delayed release formulation that is developed to alleviate GI symptoms. A comparison of the frequency and severity of GI symptoms observed in patients treated with MMF (cellcept®) after conversion to myfortic® will be measured by using a self-assessed questionnaire called Gastrointestinal Symptom Rating Scale (GSRS). To prove the incidence and improvement of GI lesions in patients treated with MMF (cellcept®) after conversion to myfortic® will be measured by using Small Bowel Capsule Endoscopy (SBCE).


Clinical Trial Description

Myfortic® recently introduced to the market has shown to be similar to MMF in how effectively it works and how well it is tolerated. Both drugs have the same active ingredient, but they are different in the way that they deliver them to the body. Myfortic® is an advanced, enteric coated formulation of mycophenolate sodium (EC-MPS) that delays the release of the active ingredient, MPA. MPA has more potent effects on the lymphocytes than other cells. This makes for improved GI tolerability of the MPA therapy. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00652834
Study type Interventional
Source University of California, Los Angeles
Contact
Status Completed
Phase Phase 4
Start date April 2009
Completion date May 2011

See also
  Status Clinical Trial Phase
Completed NCT02530762 - Acute Gastrointestinal Tolerability Following a Single Serving of a Novel Dietary Fiber N/A
Completed NCT02532985 - Gastrointestinal Tolerability Following Multiple Servings of a Novel Dietary Fiber N/A
Recruiting NCT01464814 - Clinical Trial Evaluating the Viability of L. Casei + Fish Oil Capsules N/A
Completed NCT02180035 - Treatment With Nutritional Eating Plan and Dietary Fibers in Adult Patients With HIV/AIDS N/A
Completed NCT05603403 - Efficacy And Safety Of Probiatop In The Treatment Of Digestive Symptoms Phase 4
Recruiting NCT02928484 - Evaluation of the Effect of a Probiotic Supplement Upon Gastrointestinal Function Phase 1/Phase 2
Completed NCT02519374 - Fiber Tolerability in Children N/A
Completed NCT02677090 - Fiber Tolerability in Children Aged 3-7 Year N/A
Completed NCT00822328 - Fermented Milk Drink on Human Intestinal Microflora Phase 2
Completed NCT02253628 - The Acute Effect of Coffee Consumption on Stomach, Self-reported Gastrointestinal Symptoms and Stress. N/A
Completed NCT00251992 - Nexium Dyspepsia/AST Phase 3
Completed NCT00251914 - Nexium Dyspepsia/AST Phase 3
Completed NCT01431482 - Evaluation of the Composition of Human Milk and Health Outcomes in Children
Terminated NCT01675960 - Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children Phase 2
Active, not recruiting NCT00110708 - Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism Phase 2